Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Tetramethylammonium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.31 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetramethylammonium Ion SCHEMBL7641461 | 0.95 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4SLC34A1BBOX1 | |
| Tetramethylammonium Ion SCHEMBL1204834 | 0.95 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4SLC34A1BBOX1 | |
| Tetramethylammonium Ion SCHEMBL15924284 | 0.86 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4SLC34A1 | |
| Phosphoric Acid SCHEMBL3497711 | 0.84 | SLC34A1 (0.39) | SLC34A1LMNA | |
| Tetramethylammonium Ion SCHEMBL10180356 | 0.82 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4SLC34A1 | |
| Tetramethylammonium Ion SCHEMBL11226372 | 0.82 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4SLC34A1 | |
| Tetramethylammonium Ion SCHEMBL36639 | 0.82 | SLC34A1 (0.50) | CHRNB2CHRNA7CHRNA4SLC34A1BBOX1 | |
| Tetramethylammonium Ion SCHEMBL36640 | 0.82 | SLC34A1 (0.61) | CHRNB2CHRNA7CHRNA4SLC34A1BBOX1 | |
| Tetramethylammonium Ion SCHEMBL10181373 | 0.82 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4SLC34A1 | |
| Tetramethylammonium Ion SCHEMBL6320658 | 0.79 | SLC34A1 (0.47) | CHRNB2CHRNA7CHRNA4SLC34A1BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079810-A | Aromatic diamine and polyimide containing amido, preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-121528773-B | Water-based high-voltage electrolyte, preparation method thereof and supercapacitor | Xi'an Thermal Power Research Institute Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4690281-A1 | COMPOSITION FOR TIN HARD MASK REMOVAL WHILE COMPATIBLE WITH TUNGSTEN | Versum Materials US, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260015560-A1 | COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES | ENTEGRIS INC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250381519-A1 | CO2 CONCENTRATOR AND RELATED MATERIALS, PROCESSES, AND SYSTEMS | SUSTEON INC (US) | 2025-12-18 | — | — | US | claimed |
| WO-2025104679-A1 | PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-22 | — | — | WO | claimed |
| CN-119907401-A | Photoelectric device, preparation method thereof and display device | TCL科技集团股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119876971-A | Acidic CO2Electrolytic process | 南京大学 | 2025-04-25 | — | — | CN | claimed |
| WO-2024233437-A1 | COMPOSITION FOR TIN HARD MASK REMOVAL WHILE COMPATIBLE WITH TUNGSTEN | VERSUM MATERIALS US, LLC (US) | 2024-11-14 | — | — | WO | claimed |
| CN-109705010-B | Preparation process of high-purity lisinopril | 浙江华海药业股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20140193945-A1 | SOLUTION FOR ETCHING A THIN FILM TRANSISTOR AND METHOD OF MANUFACTURING THE SAME | THE PENN STATE RESEARCH FOUNDATION | 2014-07-10 | — | — | US | claimed |
| US-20140179591-A1 | STRUCTURING USING AN EXTERNAL STRUCTURANT AND A COSMOTROPE | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-26 | — | — | US | claimed |
| WO-2014099852-A1 | IMPROVED STRUCTURING USING AN EXTERNAL STRUCTURANT AND A COSMOTROPE | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-26 | — | — | WO | claimed |
| EP-2746377-A1 | Improved structuring using an external structurant and a cosmotrope | The Procter & Gamble Company (US) | 2014-06-25 | — | — | EP | claimed |
| US-20130334063-A1 | Method of Detecting Analyte | GORDON & ROSENBLATT, LLC (US) | 2013-12-19 | — | — | US | claimed |
| US-6462005-B1 | AQUEOUS SOLUTION CONTAINING A QUARTERNARY AMMONIUM SALT, A FLUORO COMPOUND AND OPTIONALLY AN ORGANIC SOLVENT; PROTECTING DEPOSITION FILM TO BE REMOVED; NO CORROSION OF CONDUCTIVE LAYER BEING DECONTAMINATED | TEXAS INSTRUMENTS INCORPORATED | 2002-10-08 | — | — | US | claimed |
| US-5972862-A | COMPRISING A FLUORINE-CONTAINING COMPOUND, A WATER-SOLUBLE OR WATER-MISCIBLE ORGANIC SOLVENT, AN ORGANIC ACID, AND A QUATERNARY AMMONIUM SALT | MITSUBISHI GAS CHEMICAL (JP) | 1999-10-26 | — | — | US | claimed |
| EP-0529070-A1 | METHODS FOR IMPROVING THE SENSITIVITY OF HYBRIDIZATION ASSAYS | AMOCO CORPORATION (US) | 1993-03-03 | — | — | EP | claimed |
| WO-1992015708-A1 | METHODS FOR IMPROVING THE SENSITIVITY OF HYBRIDIZATION ASSAYS | AMOCO CORPORATION (US) | 1992-09-17 | — | — | WO | claimed |
| US-4522729-A | CXONTACTING IMPORITIES WITH TETRAALKYLAMMONIUM SALT | PHILLIPS PETROLEUM COMPANY (US) | 1985-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015560-A1 | COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES | TET2, ASIC1, PIEZO1 | ADRA1A 2285/4885KCNH2 411/4885CHRNB2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.